ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2018
[The mechanism and current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recurrence rate of hepatocellular carcinoma (HCC) after liver transplantation is still high, seriously affecting the long-term survival rate. The current research results show that the mechanism of postoperative recurrence of liver cancer is mainly related to residual micro-lesions, hepatitis, regeneration and immunosuppression. Milan criteria for liver transplantation, tumor vascular invasion, degree of differentiation, surgical procedures, and the use of calcineurin immunosuppressive agents are risk factors for recurrence of HCC after liver transplantation, and biomarkers such as genes and miRNAs that respond to biological characteristics of the tumor have been gradually used in HCC recurrence risk stratification and predicting prognosis. The use of mTOR inhibitors, preoperative interventional treatment before liver transplantation and non -tumor ablation technique are the main effective methods to prevent the recurrence of HCC. Hepatectomy is still the most effective treatment for patients with recurrent HCC after transplantation, and intervention with sorafenib in combination with mTOR inhibitors can benefit the survival of most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.